Vanda Pharmaceuticals recently received a decision from the U.S. FDA granting a rare formal evidentiary public hearing to review the agency’s proposed refusal to approve a supplemental new drug application for HETLIOZ (tasimelteon) as a treatment for jet lag disorder. This hearing, which follows Vanda’s earlier legal win requiring the FDA to more fully address its clinical evidence, highlights unusually high regulatory and scientific scrutiny around expanding HETLIOZ into a large, currently untreated travel-related indication. We’ll now examine how the FDA’s rare public hearing on HETLIOZ for jet lag could reshape Vanda’s risk profile and growth narrative.
Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.
Vanda Pharmaceuticals Investment Narrative Recap
To own Vanda today, you need to believe its expanding CNS and rare-disease portfolio can offset HETLIOZ generic pressure and ongoing losses, while management manages cash burn. The FDA’s rare public hearing on HETLIOZ for jet lag raises regulatory uncertainty around a potentially large indication and becomes a key near term catalyst, but also amplifies the risk that added legal and regulatory complexity could weigh on timing and costs if the outcome is unfavorable.
Against this backdrop, the recent FDA approval of BYSANTI for bipolar I and schizophrenia looks especially important, because it strengthens Vanda’s psychiatry franchise at a time when HETLIOZ faces heightened regulatory and competitive headwinds. While BYSANTI will take time to launch and build prescriptions, its approval provides another potential revenue pillar that could reduce dependence on HETLIOZ outcomes and help support the broader growth and pipeline story.
Yet in contrast, you should also be aware that if HETLIOZ’s hearing outcome disappoints and BYSANTI underperforms, Vanda’s reliance on a concentrated portfolio could…
Read the full narrative on Vanda Pharmaceuticals (it’s free!)
Vanda Pharmaceuticals’ narrative projects $432.2 million revenue and $7.7 million earnings by 2028. This requires 28.6% yearly revenue growth and a $74.6 million earnings increase from -$66.9 million today.
Uncover how Vanda Pharmaceuticals’ forecasts yield a $12.67 fair value, a 36% upside to its current price.
Exploring Other Perspectives
VNDA 1-Year Stock Price Chart
Pessimistic analysts were already assuming about US$424.9 million in 2028 revenue and continued losses, so this rare HETLIOZ hearing could either ease those psychiatry concentration worries or reinforce them.
Explore 9 other fair value estimates on Vanda Pharmaceuticals – why the stock might be worth over 5x more than the current price!
The Verdict Is Yours
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com